Biosimilar Prices May Fall Dramatically With More Than 50 Companies Looking For Market Share
This article was originally published in PharmAsia News
You may also be interested in...
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
SEOUL - South Korea's leading conglomerate Samsung Group is following in the footsteps of Korea's biosimilar front-runner Celltrion in beginning its biopharmaceutical journey as a contract manufacturing organization via a joint venture announced Jan. 25 with multinational contract research organization Quintiles Transnational Corp.
MUMBAI - India's top generic drug maker, Cipla, is speeding up its entry into biosimilars with the newly named Biomab, an equal stake joint venture with an undisclosed Chinese company
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.